Eli Lilly and Stock Forecast for 2023 - 2025 - 2030
Updated on 03/28/2024
Eli Lilly and Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by nine distinguished experts, with an average mark of $813.00. If it reached this goal, it would represent a potential upside of approximately 10.71% from the previous closing price in March, 2024. The high end is $1000.00, and the low is $500.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NYSE:BMY.
10.71% Upside
Eli Lilly and Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Eli Lilly and's Price has gone down from $250.75 to $0.00 – a 100.00% drop. In the next year, analysts believe that Fair Value will reach $371.22 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr895.10 | Buy/Sell | kr696.07 | 6.13% |
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$599.43 | Buy/Sell | $591.94 | 0.10% |
ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF242.00 | Buy/Sell | CHF307.83 | 11.57% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
Eli Lilly and Revenue Forecast for 2023 - 2025 - 2030
Eli Lilly and's Revenue has seen growth In the last three years, going from $24.54B to $34.12B – a gain of 39.06% In the next year, analysts believe that Revenue will reach $34.27B – an increase of 0.42%. For the next seven years, the forecast is forRevenue to grow by 40.51%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
Eli Lilly and Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Dividend per Share for Eli Lilly and has grown by 52.70%, going from $2.96 to $4.52. In the coming year, analysts are expecting an increase in Dividend per Share, predicting it will reach $4.68 – an increase of 3.54%. Over the next seven years, experts anticipate that Dividend per Share growth for Eli Lilly and will be 165.27%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
ZTS Stock Forecast | Zoetis | Outperform |
18
|
$183.49 | Buy/Sell | $220.47 | 20.72% |
Eli Lilly and EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Eli Lilly and's EBITDA has increased by 46.16%, going from $8.43B to $12.31B. In the next year, analysts are expecting an increase in EBITDA, predicting it will reach $14.01B – an increase of 13.76%. The Eli Lilly and forecast is for EBITDA to reach $20.45B or grow by 66.07%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4519 Stock Forecast | Chugai Pharmaceutical | Outperform |
6
|
¥6.51k | Buy/Sell | ¥4.92k | -5.57% |
SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.59k | Buy/Sell | Rp1.52k | -1.42% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
Eli Lilly and EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Eli Lilly and's EBIT has grown, increasing from $7.10B to $10.79B – an increase of 51.90%. For next year, the 17 analysts predict EBIT of $12.44B, which would mean an increase of 15.36%. Over the next seven years, the pros' prediction is EBITof $19.90B, which would mean a seven-year growth forecast of 84.45%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MRNA Stock Forecast | Moderna | Outperform |
16
|
$111.98 | Buy/Sell | $135.42 | 11.09% |
BAYN Stock Forecast | Bayer | Hold |
5
|
26.82€ | Buy/Sell | 45.15€ | 26.77% |
ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$149.10 | Buy/Sell | $245.24 | 44.20% |
Eli Lilly and EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Eli Lilly and's EPS has gone down from $7.93 to $0.00 – a 100.00% drop. In the next year, analysts believe that EPS will reach $11.74 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BGNE Stock Forecast | BeiGene | Buy |
6
|
$164.53 | Buy/Sell | $285.19 | 67.14% |
TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.35 | Buy/Sell | $11.59 | 19.85% |
4507 Stock Forecast | Shionogi & | Outperform |
18
|
¥7.87k | Buy/Sell | ¥7.12k | 1.70% |